SOX40L: An important inflammatory mediator in adult bronchial asthma

Annals of the Academy of Medicine Singapore

Volumn 41, Issue 5, 2012, Pages 200-204

  Lei, Wei ^a   Zhu, Can Hong ^b   Zeng, Da Xiong ^a   Wang, Qin ^c   Zhang, Xiu Qin ^a   Chen, Yan Bin ^a   Mu, Chuan Yong ^a   Huang, Jian An ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Co stimulatory; ELISA; Pulmonary function; Soluble OX40 ligand

Indexed keywords

OX40 LIGAND;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; SPIROMETER;

EID: 84861902435     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-87.
2. Hanania NA. Targeting airway inflammation in asthma: current and future therapies. Chest 2008;133:989-98.
3. Purdue MP, Lan Q, Martinez-Maza O, Oken MM, Hocking W, Huang WY, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 2009;114:2730-2.
4. Wang L, Chen RF, Liu JW, Yu HR, Kuo HC, Yang KD. Implications of dynamic changes among tumor necrosis factor-α (TNF-α), membrane TNF receptor, and soluble TNF receptor levels in regard to the severity of dengue infection. Am J Trop Med Hyg 2007;77:297-302.
5. Choudhury A, Chung I, Panja N, Patel J, Lip GY. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble p-selectin, stroke risk factors, and risk factor intervention. Chest 2008;134:574-81.
6. Zhang G, Xu Y, Lu X, Huang H, Zhou Y, Lu B, et al. Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer 2009;66:245-9.
7. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004;4:420-31.
8. Muller N, Wyzgol A, Munkel S, Pfizenmaier K, Wajant H. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J 2008;275:2296-304.
9. Qin W, Hongya W, Yongjing C, Fang X, Yue M, Xuekun Z, et al. Increased OX40 and soluble OX40 ligands in children with Henoch-Schonlein purpura: association with renal involvement. Pediatr Allergy Immunol 2011;22:54-9.
10. Yan J, Gong J, Chen G, Liu P, Wang C, Yang P. Evaluation of serum soluble OX40 ligand as a prognostic indicator in acute coronary syndrome patients. Clin Chim Acta 2010;411:1662-5.
11. Ezzat MH, Imam SS, Shaheen KY, Elbrhami EM. Serum OX40 ligand levels in asthmatic children: a potential biomarker of severity and persistence. Allergy Asthma Proc 2011;32:313-8.
12. Global strategy for asthma management and prevention, Global initiative for asthma (GINA) 2010. Available at http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.html. Accessed 3 April 2011.
13. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998;50:515-96.
14. Diamant Z, Boot JD, Virchow JC. Summing up 100 years of asthma. Respir Med 2007;101:378-88.
15. Miura S, Ohtani K, Numata N, Niki M, Ohbo K, Ina Y, et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol 1991;11:1313-25.
16. Weinberg AD, Evans DE, Thalhofer C, Shi T, Prell RA. The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J Leukoc Biol 2004;75:962-72.
17. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997;159:3838-48.
18. Soroosh P, Ine S, Sugamura K, Ishii N. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. J Immunol 2006;176:5975-87.
19. Suhoski MM, Perez EE, Heltzer ML, Laney A, Shaffer LG, Saitta S, et al. Monosomy 1p36 uncovers a role for OX40 in survival of activated CD4+ T cells. Clin Immunol 2008;128:181-9.
20. Soroosh P, Ine S, Sugamura K, Ishii N. Differential requirements for OX40 signals on generation of effector and central memory CD4+ T cells. J Immunol 2007;179:5014-23.
21. Wang Q, Chen Y, Ge Y, Sun J, Shi Q, Ju S, et al. Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: enhancement of IgG production of B cells and promotion of maturation of DCs. Tissue Antigens 2004;64:566-74.
22. Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009;229:173-91.
23. Hoshino A, Tanaka Y, Akiba H, Asakura Y, Mita Y, Sakurai T, et al. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol 2003;33:861-9.
24. Salek-Ardakani S, Song J, Halteman BS, Jember AG, Akiba H, Yagita H, et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 2003;198:315-24.
25. Kim MY, Anderson G, White A, Jenkinson E, Arlt W, Martensson IL, et al. OX40 ligand and CD30 ligand are expressed on adult but not neonatal CD4+CD3- inducer cells: evidence that IL-7 signals regulate CD30 ligand but not OX40 ligand expression. J Immunol 2005;174:6686-91.
26. van Oosterhout AJ, Bloksma N. Regulatory T-lymphocytes in asthma. Eur Respir J 2005;26:918-32.